fashion -WSS

fashion

author：entertainment 2025-10-01 20:13:45 - browse：6754

Adam's take main illustration — Molly Ferguson/STAT

The eye disease physician in charge of a committee that flagged a rare but severe side effect involving a newly approved drug from Apellis Pharmaceuticals has financial ties to a competing drugmaker. The conflict raises questions about his supervision of an emerging safety issue for patients and its impact on the financial health of Apellis.

Peter Kaiser, a retinal disease expert who runs the Cole Eye Institute at the Cleveland Clinic, failed to report consulting fees and stock ownership in Iveric Bio on a financial disclosure form maintained by the American Society of Retina Specialists, or ASRS. Iveric Bio is developing a treatment for geographic atrophy, a common, age-related cause of vision loss and the same indication for which the Apellis drug was approved.

The financial conflict, which was undisclosed until after Kaiser was contacted about it by STAT, is relevant because Kaiser also chairs a committee of the ASRS responsible for monitoring the safety of retina drugs and devices. On July 15, Kaiser’s committee sent a letter to member doctors, alerting them to reports of eye inflammation in people receiving injections of Syfovre, the treatment recently approved and launched by Apellis.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： U.K. Biobank has 500,000 peoples' genome sequences available

WSS

Rep. Raul Ruiz on the physician shortage and more

30 years of 'Listening to Prozac'

New Medicare drug pricing powers could soon be upended in court

Readout LOUD podcast: live from JPM 2024

GSK to buy asthma

With clinical trial data readouts, here's how to spot spin

leisure time

fashion

entertainment

In age of alternative facts, a scholarly course on calling out crap

Heart disease and mental health: A look at cardiac psychology

Virginia high school admissions case could be legal follow

HHS names first

State Dept. review finds Biden bears some blame for Afghanistan failures

New menopause drug shows promise in relief for hot flashes

George Santos makes 1st court appearance after pleading not guilty to 13 counts

GSK to buy asthma

In Memoriam: Notable people who died in 2023

Takeda, Janssen join wearable maker to measure scratching

focus

FDA investigates CAR

Will the market for weight loss drugs really reach $100 billion?

The SUPPORT Act is critical to fighting the opioid crisis

Generative AI mines health records to identify patients’ social needs

Fetal surgery at risk from Dobbs and new abortion restrictions

Doulas covered by Medicaid under New York's new plan

Wikipedia

focus

hotspot

explore